PubMed Journals Articles About "Unexpected Role Immuno Oncology SCCOHT" RSS

13:04 EDT 20th August 2018 | BioPortfolio

Unexpected Role Immuno Oncology SCCOHT PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Unexpected Role Immuno Oncology SCCOHT articles that have been published worldwide.

More Information about "Unexpected Role Immuno Oncology SCCOHT" on BioPortfolio

We have published hundreds of Unexpected Role Immuno Oncology SCCOHT news stories on BioPortfolio along with dozens of Unexpected Role Immuno Oncology SCCOHT Clinical Trials and PubMed Articles about Unexpected Role Immuno Oncology SCCOHT for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Unexpected Role Immuno Oncology SCCOHT Companies in our database. You can also find out about relevant Unexpected Role Immuno Oncology SCCOHT Drugs and Medications on this site too.

Showing "Unexpected role Immuno oncology SCCOHT" PubMed Articles 1–25 of 24,000+

Challenges in Immuno-Oncology - Possibilities for Optimization.

Immuno-oncology has undoubtedly started a new era in the treatment of malignant diseases. Within a short time immunotherapeutic therapy concepts have become part of the standard therapy for many tumors. Already, immunotherapy is one of the most potent therapeutic options for the treatment of many malignancies. Despite its impressive achievements, there is still a significant need for improvement and many aspects of the practical application of immunotherapeutic modalities of therapy are unclear. If it succe...

Rational design and identification of immuno-oncology drug combinations.

Clinical trials investigating immuno-oncology (IO) drug combinations are largely based on empiricism or limited non-clinical evaluations. This study identified the current combination IO drug clinical trials and investigated how tumour molecular profiling can help rationalise IO drug combinations.

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade.

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a highly aggressive monogenic cancer driven by SMARCA4 mutations. Here, we report responses to anti-PD1 immunotherapy in four patients and characterize the immune landscape of SCCOHT tumors using quantitative immunofluorescence and gene expression profiling. Unexpectedly for a low mutation burden cancer, the majority of the tumors (eight of 11 cases) demonstrated PD-L1 expression with strong associated T-cell infiltration (R2 = 0.60-0.95). P...

Promises and challenges of immuno-oncology from a clinical perspective.

Re: Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures.

Reply to: "Re: Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures".

Expression and Targeting of Tumor Markers in GelfoamHistoculture: Potential Individualized Assays for Immuno-Oncology.

Tumor-specific antigens are important in the study of tumor biology, tumor diagnosis, and prognosis and as targets for tumor therapy. This chapter reviews patient colon, breast, and ovarian tumors in 3-dimensional Gelfoamhistoculture maintaining in vivo-like expression of the important tumor antigens, for example TAG-72 and CEA. We have also reviewed that fluorescent antibodies can target tumors in Gelfoamhistoculture, thereby providing an assay for individual patients for sensitivity to therapeutic antibod...

Clinical Nurse Leader: Evolution of the Role in Oncology Care.

The clinical nurse leader (CNL) role has evolved since the American Association of Colleges of Nursing published a white paper on the role in 2007. Since then, various publications have evaluated the role of CNLs in enhancing quality outcomes for patients. The introduction of the CNL role in the oncology setting, although occurring with variability across the United States, provides a unique opportunity to explore the benefits of this role in cancer care outcomes.

Improving Pain Assessment and Management in Routine Oncology Practice: The Role of Implementation Research.

Immuncheckpoint Inhibitors: Current Indications and Possible Future Concepts.

Immuno-oncological therapy concepts have already achieved great success in the treatment of a number of advanced malignancies, thereby rapidly gaining access to clinical practice. Immuncheckpoint inhibitors are also being reviewed in the adjuvant setting. In malignant melanoma, they have already shown efficacy. Different combination strategies of Immuncheckpoint inhibitors are currently undergoing clinical evaluation to further improve treatment outcomes. However, this has so far also been associated with a...

A mouse model for evaluation of efficacy and concomitant toxicity of anti-human CXCR4 therapeutics.

The development of therapeutic monoclonal antibodies through mouse immunization often originates drug candidates that are not cross-reactive to the mouse ortholog. In such cases, and particularly in oncology, drug efficacy studies are performed on human tumor xenografts or with "surrogate" anti-mouse ortholog antibodies if targeting tumor host cells. Safety assessment of drug candidate(s) is performed at a later development stage in healthy non-human primates. While the latter remains necessary before a dru...

Management of oncological emergencies on the acute take.

In 2008, recommendations from the National Confidential Enquiry into Patient Outcome and Death identified large variations in the quality and safety of delivery of systemic anti-cancer therapy. In 49% of cases it was felt there was room for improvement and in 27% of cases treatment actually caused or hastened death. Every hospital with an emergency department and/or specialist oncology beds should therefore have a fully functioning acute oncology service to align acute oncology with urgent care. Many patien...

CD73 expression and clinical significance in human metastatic melanoma.

CD73 is an ectoenzyme involved in the production of adenosine. It exerts immunosuppressive and protumoral roles and has emerged as a potential immuno-oncology target.

Immuno-Oncology: A Brief Overview.

Pioneering work has unraveled the role of the immune system in the development and control of cancer. This knowledge has set the basis for the successful implementation of immunotherapy into the standard of care for a large number of cancer types. Based on response rates and prolongation of overall survival, immunotherapeutic approaches have been approved in a growing number of tumor diseases. Activation or therapeutic utilization of T cells represent the basis of these concepts. Checkpoint inhibitory anti...

Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine.

Targeting the CD73-adenosine axis in immuno-oncology.

The ectonucleotidases CD39 and CD73 are cell surface enzymes that catabolize the breakdown of extracellular ATP into adenosine. As such, they constitute critical components of the extracellular purinergic pathway and play important roles in maintaining tissue and immune homeostasis. With the coming of age of cancer immunotherapy, ectonucleotidases and adenosine receptors have emerged as novel therapeutic targets to enhance antitumor immune responses. With early-phase clinical trials showing promising result...

Short delay in initiation of radiotherapy for patients with glioblastoma- effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group (RTOG) database.

We previously reported the unexpected finding of significantly improved survival for newly-diagnosed glioblastoma patients when radiation therapy (RT) was initiated later (>4 weeks post-op) compared to earlier (≤2 weeks post-op). In that analysis, data were analyzed from 2855 patients from 16 NRG Oncology/RTOG trials conducted prior to the era of concurrent temozolomide (TMZ) with RT. We now report on 1395 newly-diagnosed glioblastoma patients from two studies, treated with RT and concurrent TMZ followed ...

American Society of Clinical Oncology Statement: Biosimilars in Oncology.

As many biosimilars come to market in the next several years, their use in oncology will play an important role in the future care of patients with cancer. ASCO is committed to providing education and guidance to the oncology community on the use of biosimilars in the cancer setting; therefore, ASCO has developed this statement to offer guidance in the following areas: (1) naming, labeling, and other regulatory considerations, (2) safety and efficacy of biosimilars, (3) interchangeability, switching, and su...

State of the Art: Advances in Malignant Pleural Mesothelioma in 2017.

Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. While recent epidemiological data demonstrated that the incidence of MPM-related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for exam...

Present and Future of Immunotherapy in the Management of Multiple Myeloma.

Multiple myeloma (MM) is the second most common hematologic malignancy with an increasing incidence and prevalence. The wide array of effective antimyeloma agents have transformed MM into a chronic condition for some patients, requiring long-term management planning. Immunomodulatory drugs and proteasome inhibitors have played a pivotal role in defining the most effective regimens for both transplantation-eligible and transplantation-ineligible subgroups. Nevertheless, recent approvals of immunotherapies in...

Jordanian oncology nurses' knowledge of managing chemotherapy-induced nausea and vomiting.

health practitioners, especially oncology nurses, play an important role in assessing and managing chemotherapy-induced nausea and vomiting (CINV). Oncology nurses need adequate knowledge and skills to optimally assess and manage CINV in oncology settings.

Radioiodine and Its Relationship to Hematologic Malignancy: The Confounding Role of Supraphysiologic Thyroxine.

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

Demonstration of IgG Subclass (IgG1 and IgG3) in Immuno-Related Hemocytopenia.

Immuno-related hemocytopenia (IRH) is defined as idiopathic cytopenia of undetermined significance (ICUS) patients with autoantibodies. In our previous studies, we found that IgG1 levels were increased in IRH patients and might cause the destruction of hematopoietic cells.

Next generation neuro-oncology.

Neuro-oncology has evolved as a growing, but still small, highly specialised and multidisciplinary field at the interface of several diagnostic and therapeutic disciplines. The major challenge in the field of primary tumours is to translate the almost unique progress in deciphering the highly complex molecular genetic nature of many primary brain tumours, notably glioblastoma, into advances that allow for clinical benefit for affected patients. Furthermore, metastases to the central nervous system are an in...

Quick Search